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RikkunshitoisapopularJapanesetraditionalmedicinethatisprescribedinJapantotreatvariousgastrointestinaltractdisorders.In
a double-blind controlled study, rikkunshito signiﬁcantly ameliorated dysmotility-like dyspepsia and brought about a generalized
improvement in upper gastric symptoms such as nausea and anorexia when compared with a control group. Several studies in
rats have shown enhanced gastric emptying and a protective eﬀect on gastric mucosa injury with rikkunshito administration. In
addition, rikkunshito in combination with an anti-emetic drug is eﬀective against anorexia and vomiting that occur as adverse
reactions to chemotherapy in patients with advanced breast cancer. However, the mechanism by which rikkunshito alleviates
gastrointestinal disorders induced by anticancer agents remains unclear. It has recently been shown that rikkunshito ameliorates
cisplatin-induced anorexia by mediating an increase in the circulating ghrelin concentration. Moreover, Fujitsuka et al. found that
decreased contractions of the antrum and duodenum in rats treated with a selective serotonin reuptake inhibitor were reversed
by rikkunshito via enhancement of the circulating ghrelin concentration. These ﬁndings show that rikkunshito may be useful for
treatment of anorexia and may provide a new strategy for improvement of upper gastrointestinal dysfunction.
Rikkunshito is one of the few traditional Japanese medicines
forwhichadouble-blindstudyhasbeenconducted.Thistrial
wasperformedinpatientswithdysmotility-likedyspepsia[1,
2] based on a report that rikkunshito showed eﬃcacy against
non-ulcerdyspepsia,whichisanolddiagnosticclassiﬁcation.
In a subsequent comparative clinical study, rikkunshito was
found to be more eﬀective than cisapride against undeﬁned
gastrointestinal complaints such as chronic gastritis [3].
Rikkunshito is prepared by compounding eight herbal
medicines listed in the Japanese Pharmacopoeia: Atractylodis
Lanceae Rhizoma, Ginseng Radix, Pinelliae Tuber, Hoelen,
Zizyphi Fructus, Aurantii Nobilis Pericarpium, Glycyrrhizae
Radix and Zingiberis Rhizoma. It has recently been shown
that oral administration of rikkunshito stimulates secretion
of the orexigenic peptide, ghrelin, from the stomach [4, 5].
Inthissection,theeﬀectsofrikkunshitoareintroduced,with
main focus on the action of rikkunshito as an enhancer of
ghrelin secretion.
Anorexia is commonly seen in gastrointestinal diseases,
althoughitisnotaspeciﬁcsymptom.Anorexiaisparticularly
common in chronic gastritis and gastric cancer but also
occurs in acute hepatitis, hepatic cirrhosis, chronic pancre-
atitis, and chronic cholecystitis. Harasawa et al. [1] showed
that rikkunshito promotes improvement of anorexia in a
double-blind study in patients with functional dyspepsia
(FD). A combination of rikkunshito plus serotonion (5-
hydroxytriptamine, 5-HT)and 3 receptor antagonist (an
anti-emetic agent) reduced anorexia and vomiting induced
as adverse reactions after chemotherapy in patients with
advanced lung cancer, compared with administration of the
anti-emetic agent alone [6]. Similarly, administration of a
selective serotonin reuptake inhibitor (SSRI), ﬂuvoxamine,
in combination with rikkunshito for eight weeks resulted in
a signiﬁcant reduction in the number of patients who com-
plained of adverse events, especially retching, compared with
SSRIadministrationalone[7].Thegastrointestinalsymptom
rating score also signiﬁcantly improved within two weeks
of starting coadministration of the SSRI with rikkunshito
[7]. These ﬁndings suggest that rikkunshito suppresses the
onset of adverse reactions to frequently prescribed drugs
that cannot be treated adequately by adjuvant therapy with
current Western medicines.
Cisplatin has been shown to cause a signiﬁcant decrease
in plasma ghrelin and food intake in rodents [4], and
intravenousinjectionofexogenousacylatedghrelininhibited
the decrease in food intake after cisplatin administration.2 International Journal of Peptides
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Figure 1: Schematic diagram of action mechanisms of rikkunshito on appetite.
Rikkunshito also inhibited the decrease in circulating ghre-
lin concentration and ameliorated the decrease in food
intake caused by cisplatin. Interestingly, coadministration
of a ghrelin receptor antagonist, [D-Lys3]-GHRP-6, with
rikkunshito abolished this eﬀect. These ﬁndings suggest that
the mechanism of improvement of anorexia by rikkunshito
may involve ghrelin receptor activation via stimulation
of ghrelin secretion from the stomach into the plasma.
Heptamethoxyﬂavone, an active ingredient ﬂavonoid in
rikkunshito, has been shown to have a pivotal eﬀect on stim-
ulation of ghrelin secretion. In addition, P388-bearing mice
showed a tendency for improved survival with rikkunshito
treatment, and survival was further improved by treatment
with cisplatin in combination with rikkunshito, although the
diﬀerence was not signiﬁcant [8]. These results show that
administration of rikkunshito has no adverse eﬀect on the
anticancer action of cisplatin itself.
Fujitsuka et al. showed that oral administration of
rikkunshitorestoresdisturbedmotoractivityinthegastroin-
testinal tract and improves anorexia in rats administered
SSRIs [5]. Intraperitoneal administration of fenﬂuramine
or ﬂuvoxamine shifted fasted rats from a fasted-like motor
pattern in the antrum and duodenum to fed-like motor
activities similar to those seen after feeding. A signiﬁcant
decrease in the plasma concentration of acylated ghrelin,
delayed gastric emptying, and decreased food intake were
also observed after administration of the SSRI. Concomitant
oral administration of rikkunshito with an SSRI suppressed
the decrease in plasma acylated ghrelin, changed the fed-
like motor activity to fasted activity, improved anorexia,
and enhanced gastric emptying. These eﬀects were abolished
by coadministration of a ghrelin receptor antagonist with
rikkunshito.
Cisplatin and SSRIs are widely used in clinical practice.
5-HT is a key factor in adverse reactions to these drugs, since
bothstimulateproductionofexcess5-HTandsuppress5-HT
metabolism in vivo. Thus, it is of interest that involvement
of the 5-HT2 receptor in appetite control has recently been
shown [9]; speciﬁcally, appetite is suppressed when the 5-
HT2B receptor in gastric smooth muscle and the 5-HT2C
receptor in the central nervous system are activated by
receptor agonists. 5-HT produced during treatment with
cisplatin or SSRIs binds to various receptor subtypes and is
likely to stimulate the 5-HT2B and 2C receptors. A decrease
in plasma ghrelin is suppressed by administration of antag-
onists for these receptors, leading to improvements in food
intake and gastrointestinal dysmotility [4, 5]. Isoliquiriti-
genin, heptamethoxyﬂavone and hesperidin are ingredients
of rikkunshito that have been shown to antagonize 5-HT2B
and 2C receptors [4]; thus, these ingredients are considered
to play an important role in the improvement of appetite
by rikkunshito. Administration of hesperidin reverses the
decrease in plasma ghrelin in cisplatin-treated rats and shifts
the fed-like motor pattern induced by SSRI administration
to a fasted pattern. Thus, 5-HT2C antagonism by active
components in rikkunshito may lead to the improvement of
anorexia.
More recent report demonstrated that administration
of rikkunshito improve anorexia of aging via inhibiting a
reduced hypothalamic ghrelin receptor reactivity [10]. The
data indicated that aging-associated anorexia is caused by
an increase in plasma leptin, which results from disturbedInternational Journal of Peptides 3
reactivity of ghrelin in the hypothalamus and regulation of
ghrelin secretion. Oral administration of cilostamide, phos-
phodiesterase type 3 (PDE3) inhibitor improved anorexia
in aged mice. The components of rikkunshito (nobiletin,
isoliquiritigenin, and heptamethoxyﬂavone) had inhibitory
eﬀects on PDE3 activity. Dysregulation of ghrelin secretion
andghrelinresistanceintheappetitecontrolsystemoccurred
in aged mice and that rikkunshito ameliorated aging-
anorexia via inhibition of PDE3.
In summary, administration of rikkunshito stimulates
secretion of ghrelin from stomach via peripheral 5-HT2B
and central 5-HT2C receptor antagonism as seen in Figure 1.
Moreover, rikkunshito is also an enhancement of ghrelin
receptor reactivity via PDE3 inhibition. These studies raise
the possibility of using rikkunshito to treat anorexia.
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